L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
出版年份 2017 全文链接
标题
L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 3, Pages 482
出版商
MDPI AG
发表日期
2017-02-24
DOI
10.3390/ijms18030482
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
- (2015) Michael Juchum et al. DRUG RESISTANCE UPDATES
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
- (2015) Ivana Sullivan et al. Therapeutic Advances in Medical Oncology
- Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer
- (2014) Namrata Vijayvergia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations
- (2014) Rashmi Kumari et al. Journal of Chemical Information and Modeling
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
- (2013) Sander Pronk et al. BIOINFORMATICS
- Molecular Dynamics Simulation of Tryptophan Hydroxylase-1: Binding Modes and Free Energy Analysis to Phenylalanine Derivative Inhibitors
- (2013) Hao Zhong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Global estimates of cancer prevalence for 27 sites in the adult population in 2008
- (2012) Freddie Bray et al. INTERNATIONAL JOURNAL OF CANCER
- Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method
- (2012) Nadine Homeyer et al. Molecular Informatics
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation
- (2007) Berk Hess Journal of Chemical Theory and Computation
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started